Attention is focusing on whether Eli Lilly can commercialize another blockbuster drug in the global obesity drug market worth 13 trillion won by entering phase 3 clinical trials for new drug candidates, Orforglipron and Retatrutide. According to related industries, the Ministry of Food and Drug Safety approved the phase 3 clinical trial to confirm the effect of once-weekly administration of Retatrutide in obese or overweight type 2 diabetes subjects in mid-March last month.

Orforglipron also recently announced the results of its phase 2 clinical trial through the American Diabetes Association and is preparing for a global phase 3 clinical trial. Both candidates are a class of glucagon-like peptide-1 (G